PEAKS Webinar Series 2026 returns for another instructive session, this time providing solutions for antibody characterisation! Join us on April 1st, 2026, as our talented Principal Scientist, Jacky Jhingree, PhD, will be leading a 45-minute lecture on our solutions for "Comprehensive Antibody Characterisation: Intact Mass and Bottom-Up Enhanced Top/Middle-Down Mass Spectrometry".
Mass spectrometry (MS) solves the most critical hurdles in antibody characterisation by providing a high-resolution map of structural heterogeneity that traditional assays miss. It precisely sequences an antibody and localises complex post-translational modifications (PTMs) like glycosylation and oxidation, which are vital for ensuring drug safety, efficacy and potency.
Integrating Intact Mass, Top/Middle-down and Bottom-up MS provides a multi-level solution to the uncertainties in biophysical properties of antibodies. Intact mass analysis offers a global "bird's-eye view," rapidly identifying major glycoforms and confirming the overall molecular weight to detect and measure large-scale degradation, truncation and impurities. Bottom-up MS at the peptide level provides high-sensitivity sequence confirmation and precise localisation of PTMs like oxidation or deamidation. Bridging the two, Top/Middle-down MS interrogates intact proteins or large subunits in the gas phase, preserving relationships between modifications and proteoforms and revealing how multiple PTMs coexist on a single molecule—a feat not possible with peptide-level analysis alone.
From complete antibody characterisation to determining critical quality attributes of protein therapeutics, discover how our latest software platform ProteoformX™ combines multiple approaches to deliver clinical ready results.
Stick around after the session for Q&A, where we'll tackle your application-specific questions!
What You'll Learn
- Streamlined Characterisation Workflows: Discover how our lab services and proprietary software streamline pharmaceutical workflows for deep antibody characterisation.
- Multi-Level Pipeline: Explore our "experiment-to-analysis" framework that synergises intact mass, top/middle-down, and bottom-up MS strategies to provide a detailed map of the proteoform landscape, from primary sequence confirmation to complex PTM co-occurrence.
- Intact Mass Analysis: Comprehensive proteoform and glycoform profiling with resolution of chain-specific PTMs, truncations, (mis)pairing and impurity identification.
- Bottom‑up enhanced Top/Middle‑Down MS: Learn how integrating peptide‑level evidence with intact subunit fragmentation enables confident sequence validation and resolution of PTM co‑occurrence.
- Versatility Across Case Studies: Review data demonstrating the platform’s performance across increasingly complex antibody systems, including monoclonal antibodies, antibody mixtures, and bispecific formats.
Who Should Attend?
- Analytical scientists responsible for antibody characterisation and CQAs
- Mass spectrometry specialists working with Intact, Top/Middle-down, or Bottom-up MS
- Biopharma teams developing complex antibody modalities (mAbs, BsAbs, mixtures)
- CMC and quality stakeholders evaluating structural heterogeneity, PTMs, and product risk
Event Details
Date: Wednesday, April 1st, 2026
Times: 10:00 a.m. & 4:00 p.m. EDT (two sessions to accommodate global audiences)
Format: Virtual (Zoom links sent upon registration confirmation)
Ready to elevate your proteomics capabilities? Secure your spot today!